Spaeth Michael, Briley Mike
Rheumatologische Schwerpunktpraxis, Gräfelfing/München, Germany.
Hum Psychopharmacol. 2009 Jun;24 Suppl 1:S3-10. doi: 10.1002/hup.1030.
Fibromyalgia is a pain syndrome which is not due to tissue damage or inflammation and is thus fundamentally different from rheumatic disorders and many other pain conditions. In addition to widespread pain it is associated with a range of other symptoms such as sleep disturbance, fatigue, cognitive disturbance, stiffness and depressive symptoms. A number of multidisciplinary therapeutic programmes involving education, exercise and cognitive therapy have been shown to be effective in bringing relief. The various medications that are currently being developed for the treatment of fibromyalgia are based on different mechanistic approaches. In particular, serotonin noradrenaline reuptake inhibitors (SNRI) such as duloxetine and milnacipran and alpha2-delta receptor ligands such as pregabalin have been shown, in a variety of placebo-controlled studies, to bring significant relief from pain and other symptoms. The complex symptomatology of fibromyalgia will, however, continue to require a multidisciplinary approach including education and exercise in addition to drug therapy to achieve the most efficient management of fibromyalgia.
纤维肌痛是一种疼痛综合征,并非由组织损伤或炎症引起,因此与风湿性疾病和许多其他疼痛状况有着根本区别。除了广泛的疼痛外,它还伴有一系列其他症状,如睡眠障碍、疲劳、认知障碍、僵硬和抑郁症状。一些涉及教育、锻炼和认知疗法的多学科治疗方案已被证明在缓解症状方面有效。目前正在研发的用于治疗纤维肌痛的各种药物基于不同的作用机制。特别是,在各种安慰剂对照研究中,度洛西汀和米那普明等5-羟色胺去甲肾上腺素再摄取抑制剂(SNRI)以及普瑞巴林等α2-δ受体配体已被证明能显著缓解疼痛和其他症状。然而,纤维肌痛复杂的症状仍将需要多学科方法,包括教育、锻炼以及药物治疗,以实现对纤维肌痛最有效的管理。